SAB BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares
SAB BIOTHERAPEUTICS, INC. (SABS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares of 147.85 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for the quarter ending 2026-06-30 was 147.85K shares, a 30.81% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for the quarter ending 2026-03-31 was 150.85K shares, a 46.47% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for the quarter ending 2025-12-31 was 130.74K shares, a 356.18% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for the quarter ending 2025-09-30 was 420.82K shares, a 155.47% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for fiscal 2025 was 950.44K shares, a 209.27% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for fiscal 2024 was 307.32K shares, a 175.09% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for fiscal 2023 was 111.71K shares, a 76.02% increase from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for fiscal 2022 was 63.47K shares, a 86.25% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 147.85K shares 10-Q · filed 2026-08-06 | 295.80K shares 10-Q · filed 2026-08-06 | 429.43K shares derived: sum of 3 quarters · filed 2026-08-06 | 850.26K shares derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | 150.85K shares 10-Q · filed 2026-05-12 | 281.59K shares derived: sum of 2 quarters · filed 2026-05-12 | 702.41K shares derived: sum of 3 quarters · filed 2026-05-12 | 815.43K shares derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | 130.74K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 551.56K shares derived: sum of 2 quarters · filed 2026-03-09 | 664.59K shares derived: sum of 3 quarters · filed 2026-08-06 | 950.44K shares 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | 420.82K shares 10-Q · filed 2025-11-14 | 533.85K shares derived: sum of 2 quarters · filed 2026-08-06 | 819.70K shares 10-Q · filed 2025-11-14 | 844.32K shares derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | 113.02K shares 10-Q · filed 2026-08-06 | 115.22K shares 10-Q · filed 2025-08-07 | 394.84K shares 10-Q · filed 2026-08-06 | 400.28K shares 10-Q · filed 2025-08-07 | 423.50K shares derived: sum of 3 quarters · filed 2026-08-06 | 588.22K shares derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | 281.81K shares 10-Q · filed 2026-05-12 | 285.06K shares 10-Q · filed 2025-05-09 | 310.47K shares derived: sum of 2 quarters · filed 2026-05-12 | 475.20K shares derived: sum of 3 quarters · filed 2026-05-12 | 511.42K shares derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | 28.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 193.39K shares derived: sum of 2 quarters · filed 2026-03-09 | 229.60K shares derived: sum of 3 quarters · filed 2026-03-09 | 307.32K shares 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | 164.73K shares 10-Q · filed 2025-11-14 | 200.94K shares derived: sum of 2 quarters · filed 2025-11-14 | 278.66K shares 10-Q · filed 2025-11-14 | 297.95K shares derived: sum of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | 36.22K shares 10-Q · filed 2025-08-07 | 114.37K shares 10-Q · filed 2025-08-07 | 133.23K shares derived: sum of 3 quarters · filed 2025-08-07 | 194.14K shares derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | 76.76K shares 10-Q · filed 2025-05-09 | 88.34K shares 10-Q · filed 2024-05-20 | 97.01K shares derived: sum of 2 quarters · filed 2025-05-09 | 157.92K shares derived: sum of 3 quarters · filed 2025-05-09 | 167.12K shares derived: sum of 4 quarters · filed 2025-05-09 | |||
| 2023-12-31 | 20.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 81.16K shares derived: sum of 2 quarters · filed 2025-03-31 | 90.35K shares derived: sum of 3 quarters · filed 2025-03-31 | 111.71K shares 10-K · filed 2025-03-31 | 124.53K shares 10-K · filed 2024-03-29 | |||
| 2023-09-30 | 60.91K shares 10-Q · filed 2024-11-06 | 619.10K shares 10-Q · filed 2023-11-13 | 70.10K shares derived: sum of 2 quarters · filed 2024-11-06 | 91.47K shares 10-Q · filed 2024-11-06 | 924.72K shares 10-Q · filed 2023-11-13 | -159.45K shares derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | 9.19K shares 10-Q · filed 2024-08-08 | 167.00K shares 10-Q · filed 2023-08-21 | 30.55K shares 10-Q · filed 2024-08-08 | 381.00K shares 10-Q · filed 2023-08-21 | -220.36K shares derived: sum of 3 quarters · filed 2024-08-08 | -111.75K shares derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | 21.36K shares 10-Q · filed 2024-05-20 | 213.00K shares 10-Q · filed 2023-05-15 | -229.55K shares derived: sum of 2 quarters · filed 2024-05-20 | -120.94K shares derived: sum of 3 quarters · filed 2024-05-20 | 14.06K shares derived: sum of 4 quarters · filed 2024-05-20 | |||
| 2022-12-31 | -250.91K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -142.30K shares derived: sum of 2 quarters · filed 2024-03-29 | -7.30K shares derived: sum of 3 quarters · filed 2024-03-29 | 63.47K shares 10-K · filed 2024-03-29 | 634.66K shares 10-K · filed 2023-04-14 | |||
| 2022-09-30 | 108.61K shares 10-Q · filed 2023-11-13 | 243.61K shares derived: sum of 2 quarters · filed 2023-11-13 | 314.38K shares 10-Q · filed 2023-11-13 | 545.34K shares derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | 135.00K shares 10-Q · filed 2023-08-21 | 134.99K shares 10-Q · filed 2022-08-10 | 315.00K shares 10-Q · filed 2023-08-21 | 315.37K shares 10-Q · filed 2022-08-10 | 436.73K shares derived: sum of 3 quarters · filed 2023-08-21 | 557.35K shares derived: sum of 4 quarters · filed 2023-08-21 | ||
| 2022-03-31 | 192.00K shares 10-Q · filed 2023-05-15 | 192.40K shares 10-Q · filed 2022-05-12 | 301.73K shares derived: sum of 2 quarters · filed 2023-05-15 | 422.35K shares derived: sum of 3 quarters · filed 2023-05-15 | 573.93K shares derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | 109.73K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | 230.35K shares derived: sum of 2 quarters · filed 2023-04-28 | 381.93K shares derived: sum of 3 quarters · filed 2023-04-28 | 461.70K shares 10-K/A · filed 2023-04-28 | ||||
| 2021-09-30 | 120.63K shares 10-Q · filed 2022-11-14 | 272.20K shares derived: sum of 2 quarters · filed 2022-11-14 | 351.97K shares 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | 151.58K shares 10-Q · filed 2022-08-10 | 231.35K shares 10-Q · filed 2022-08-10 | ||||||
| 2021-03-31 | 79.77K shares 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | 400.63K shares 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |